Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Pharmacologic Normalization of Altered Transcriptome of SF3B1 Mutant Myeloid Neoplasia

Blood (2019) 134 (Supplement_1): 564.

https://doi.org/10.1182/blood-2019-129189

Published: 2019

Journal Articles

CUL1: Novel Therapeutic Target in Myeloid Neoplasms Harboring -7/Del(7q)

Blood (2019) 134 (Supplement_1): 1281.

https://doi.org/10.1182/blood-2019-129196

Published: 2019

Journal Articles

Development of a Novel Class of Agents Targeting the RNA-Splicing Machinery in Myeloid Malignancies

Blood (2018) 132 (Supplement 1): 211.

https://doi.org/10.1182/blood-2018-99-116411

Published: 2018

Journal Articles

Paraneoplastic Leukemoid Reaction Associated with Increased Levels of and Tumor Overexpression of Receptors for G-CSF, GM-CSF, and IL-6: A Clinico-Pathological-Molecular Study

Alejandro Recio Boiles, MD, Eric M. Lander, MD, George S. Watts, PhD, Steffan T. Nawrocki, PhD, Andrew M. Yeager, MD

Blood (2018) 132 (Supplement 1): 4945.

https://doi.org/10.1182/blood-2018-99-115736

Published: 2018

Journal Articles

Oncolytic Reovirus Is an Effective Treatment for Histone Deacetylase Inhibitor Resistant T-Cell Lymphoma

Shariful Islam, Claudia M Espitia, Ning Qu, MD PhD, Daniel Persky, MD, Jennifer S. Carew, PhD, Steffan T. Nawrocki, PhD

Blood (2018) 132 (Supplement 1): 2941.

https://doi.org/10.1182/blood-2018-99-119152

Published: 2018

Journal Articles

Activation of Autophagy in Models of SF3B1 Mutant MDS

Blood (2017) 130 (Supplement 1): 4230.

https://doi.org/10.1182/blood.V130.Suppl_1.4230.4230

Published: 2017

Journal Articles

Distinct Clinical Phenotypes of Patients with Myeloid Neoplasms Carrying SF3B1 Hotspot Mutations

Blood (2017) 130 (Supplement 1): 2961.

https://doi.org/10.1182/blood.V130.Suppl_1.2961.2961

Published: 2017

Journal Articles

Oncolytic Reovirus Sensitizes Multiple Myeloma Cells to Anti-PD-L1 Therapy

Kevin R Kelly, MD PhD, Claudia M Espitia, Weiguo Zhao, Kaijin Wu, Valeria Visconte, PhD, Faiz Anwer, MD, Christine M Calton, PhD, Jennifer S. Carew, PhD, Steffan T. Nawrocki, PhD

Blood (2017) 130 (Supplement 1): 3137.

https://doi.org/10.1182/blood.V130.Suppl_1.3137.3137

Published: 2017

Journal Articles

A Novel Oncolytic Reovirus Immune Priming Strategy Dramatically Enhances the Efficacy of Anti-PD-L1 Antibody Therapy Against Multiple Myeloma

Kevin R. Kelly, MD PhD, Claudia M. Espitia, Weiguo Zhao, Valeria Visconte, PhD, Matt Coffey, Jennifer S. Carew, PhD, Steffan T. Nawrocki, PhD

Blood (2016) 128 (22): 3960.

https://doi.org/10.1182/blood.V128.22.3960.3960

Published: 2016

Journal Articles

Targeting Autophagy in Myelodysplastic Syndromes

Valeria Visconte, PhD, Steffan T. Nawrocki, PhD, Bartlomiej P Przychodzen, MSc, Kevin R. Kelly, MD PhD, Mei Yin, Yvonne Parker, Michael J. Clemente, M.S., John Barnard, PhD, Anjali S. Advani, MD, Hetty E. Carraway, MD MBA, Mikkael A. Sekeres, MD MS, Daniel Lindner, Heesun J Rogers, MD PhD, Jaroslaw P Maciejewski, MD PhD FACP, Jennifer S. Carew, PhD

Blood (2016) 128 (22): 4295.

https://doi.org/10.1182/blood.V128.22.4295.4295

Published: 2016

Journal Articles

Genetic and Epigenetic Defects in the Autophagy Machinery in Myelodysplastic Syndromes

Valeria Visconte, PhD, Bartlomiej P Przychodzen, MSc, Steffan T. Nawrocki, PhD, Swapna Thota, MD, Kevin R. Kelly, MD PhD, Bhumika Patel, MD, Cassandra M. Hirsch, BSc, Hetty E. Carraway, MD MBA, Yvonne Parker, Daniel Lindner, Mikkael A. Sekeres, MD MS, Heesun J Rogers, MD PhD, Jaroslaw P. Maciejewski, MD, PhD, FACP, Jennifer S. Carew, PhD

Blood (2016) 128 (22): 4301.

https://doi.org/10.1182/blood.V128.22.4301.4301

Published: 2016

Journal Articles

Oncolytic Reovirus Immune Priming: A Phase 1b Study of Reolysin with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Kevin R. Kelly, MD PhD, Kaijin Wu, PhD, Denice Tsao-Wei, Susan Groshen, Timothy Junius Triche, Jr., PhD, Ann Mohrbacher, Grace Chang, MD, Donna Fernando, Imran N Siddiqi, MD PhD, Matt Coffey, George Gill, Amy Lee, Jennifer S. Carew, PhD, Steffan T. Nawrocki, PhD

Blood (2016) 128 (22): 4507.

https://doi.org/10.1182/blood.V128.22.4507.4507

Published: 2016

Journal Articles

Development of ROC-325: A Novel Small Molecule Inhibitor of Autophagy with Promising Anti-Leukemic Activity

Steffan T. Nawrocki, PhD, Yingchun Han, MD, Valeria Visconte, PhD, James G Phillips, PhD, Bartlomiej P Przychodzen, MSc, Jaroslaw P Maciejewski, MD PhD FACP, Kevin R. Kelly, MD PhD, Jennifer S. Carew, PhD

Blood (2016) 128 (22): 525.

https://doi.org/10.1182/blood.V128.22.525.525

Published: 2016

Journal Articles

Activation of the Unfolded Protein Response with the First-in-Class P97 Inhibitor CB-5083 Induces Stable Disease Regression and Overcomes Ara-C Resistance in AML

Steffan T. Nawrocki, PhD, Yingchun Han, MD, Ronan LE Moigne, PhD, Valeria Visconte, PhD, Bartlomiej Przychodzen, MSc, Mark Rolfe, PhD, Stevan Djakovic, PhD, Daniel Anderson, David Wustrow, PhD, Han-Jie Zhou, Steve Wong, PhD, Anjali Advani, MD, Hetty E. Carraway, MD MBA, Jaroslaw P. Maciejewski, MD PhD, Mikkael A. Sekeres, MD MS, Kevin R. Kelly, MD PhD, Jennifer S. Carew, PhD

Blood (2015) 126 (23): 1350.

https://doi.org/10.1182/blood.V126.23.1350.1350

Published: 2015

Journal Articles

Comprehensive Quantitative Proteomic Profiling of the Pharmacodynamic Changes Induced By MLN4924 in Acute Myeloid Leukemia Cells Reveals Rational Targets for Combination Therapy

Valeria Visconte, PhD, Steffan T. Nawrocki, PhD, Kevin R. Kelly, MD PhD, Yingchun Han, MD, Anthony Possemato, Sean Beausoleil, Aziz Nazha, MD, Jaroslaw P. Maciejewski, MD PhD, Hetty E. Carraway, MD MBA, Anjali S. Advani, MD, Mikkael A. Sekeres, MD MS, Jennifer S. Carew, PhD

Blood (2015) 126 (23): 1271.

https://doi.org/10.1182/blood.V126.23.1271.1271

Published: 2015

Journal Articles

Antagonizing HDAC6 Activity: A New Strategy to Maximize the Anti-Myeloma Effects of BET Inhibition

Jennifer S. Carew, PhD, Claudia M. Espitia, Weiguo Zhao, Valeria Visconte, PhD, Kevin R. Kelly, MD PhD, Steffan T. Nawrocki, PhD

Blood (2015) 126 (23): 3022.

https://doi.org/10.1182/blood.V126.23.3022.3022

Published: 2015

Journal Articles

Elevated Basal Autophagy in SF3B1 Mutated Myelodysplastic Syndromes: Relationship with Survival Outcomes and Therapeutic Implications

Valeria Visconte, PhD, Kevin R. Kelly, MD PhD, Steffan T. Nawrocki, PhD, Yingchun Han, MD, Hetty E. Carraway, MD MBA, Anjali S. Advani, MD, Jaroslaw P. Maciejewski, MD PhD, Heesun J Rogers, MD PhD, Mikkael A. Sekeres, MD MS, Jennifer S. Carew, PhD

Blood (2015) 126 (23): 1647.

https://doi.org/10.1182/blood.V126.23.1647.1647

Published: 2015

Journal Articles

Small Molecule Inhibition of SIRT Activity: A Novel Therapeutic Approach for Refractory Multiple Myeloma

Steffan T. Nawrocki, PhD, Claudia M. Espitia, Valeria Visconte, PhD, Yingchun Han, MD, Kevin R. Kelly, MD PhD, Jennifer S. Carew, PhD

Blood (2015) 126 (23): 1807.

https://doi.org/10.1182/blood.V126.23.1807.1807

Published: 2015

Journal Articles

Inhibition of p97 with the First-in-Class Small Molecule CB-5083: A Novel Strategy for Acute Myeloid Leukemia Therapy

Rita Tohme, BS, Ronan Le Moigne, PhD, Bartlomiej P Przychodzen, Yingchun Han, MD, Mark Rolfe, PhD, Hetty E. Carraway, MD, Stevan Djakovic, PhD, Dan Anderson, PhD, David Wustrow, PhD, Han-Jie Zhou, PhD, Steve Wong, Kevin R. Kelly, MD, Yogen Saunthararajah, MD, Anjali S. Advani, MD, Jaroslaw P. Maciejewski, MD PhD, Mikkael A. Sekeres, MD MS, Steffan T. Nawrocki, PhD, Jennifer S. Carew, PhD

Blood (2014) 124 (21): 3766.

https://doi.org/10.1182/blood.V124.21.3766.3766

Published: 2014

Journal Articles

Targeting HDAC6 Is a Novel Approach to Augment the Therapeutic Benefit of Bromodomain Inhibition in Multiple Myeloma

Jennifer S. Carew, PhD, Claudia M. Espitia, MS, Weiguo Zhao, MS, Kevin R. Kelly, MD, Steffan T. Nawrocki, PhD

Blood (2014) 124 (21): 4760.

https://doi.org/10.1182/blood.V124.21.4760.4760

Published: 2014

NARROW

Pharmacologic Normalization of Altered Transcriptome of SF3B1 Mutant Myeloid Neoplasia

CUL1: Novel Therapeutic Target in Myeloid Neoplasms Harboring -7/Del(7q)

Development of a Novel Class of Agents Targeting the RNA-Splicing Machinery in Myeloid Malignancies

Paraneoplastic Leukemoid Reaction Associated with Increased Levels of and Tumor Overexpression of Receptors for G-CSF, GM-CSF, and IL-6: A Clinico-Pathological-Molecular Study

Oncolytic Reovirus Is an Effective Treatment for Histone Deacetylase Inhibitor Resistant T-Cell Lymphoma

Activation of Autophagy in Models of SF3B1 Mutant MDS

Distinct Clinical Phenotypes of Patients with Myeloid Neoplasms Carrying SF3B1 Hotspot Mutations

Oncolytic Reovirus Sensitizes Multiple Myeloma Cells to Anti-PD-L1 Therapy

A Novel Oncolytic Reovirus Immune Priming Strategy Dramatically Enhances the Efficacy of Anti-PD-L1 Antibody Therapy Against Multiple Myeloma

Targeting Autophagy in Myelodysplastic Syndromes

Genetic and Epigenetic Defects in the Autophagy Machinery in Myelodysplastic Syndromes

Oncolytic Reovirus Immune Priming: A Phase 1b Study of Reolysin with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Development of ROC-325: A Novel Small Molecule Inhibitor of Autophagy with Promising Anti-Leukemic Activity

Activation of the Unfolded Protein Response with the First-in-Class P97 Inhibitor CB-5083 Induces Stable Disease Regression and Overcomes Ara-C Resistance in AML

Comprehensive Quantitative Proteomic Profiling of the Pharmacodynamic Changes Induced By MLN4924 in Acute Myeloid Leukemia Cells Reveals Rational Targets for Combination Therapy

Antagonizing HDAC6 Activity: A New Strategy to Maximize the Anti-Myeloma Effects of BET Inhibition

Elevated Basal Autophagy in SF3B1 Mutated Myelodysplastic Syndromes: Relationship with Survival Outcomes and Therapeutic Implications

Small Molecule Inhibition of SIRT Activity: A Novel Therapeutic Approach for Refractory Multiple Myeloma

Inhibition of p97 with the First-in-Class Small Molecule CB-5083: A Novel Strategy for Acute Myeloid Leukemia Therapy

Targeting HDAC6 Is a Novel Approach to Augment the Therapeutic Benefit of Bromodomain Inhibition in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only